北美传染病治疗市场预测至 2030 年 - 区域分析 - 按药物类别(抗病毒、抗菌、抗真菌等)、适应症(艾滋病毒、肝炎、结核病、流感、HPV 等)、给药途径(口服、肠胃外、外用等)和分销渠道(医院药房、零售药房等)

BMIRE00030503 | Pages: 100 | Pharmaceuticals | Jul 2024 | Type: Regional | Status: Published
2022 年北美传染病治疗市场价值为 463.7653 亿美元,预计到 2030 年将达到 659.5597 亿美元;预计 2022 年至 2030 年的复合年增长率为 4.5%。

传染病流行率上升推动北美传染病治疗市场发展

传染病是由病毒、寄生虫、细菌、真菌、有毒物质和其他传染性病原体引起的。艾滋病毒是全世界的一个主要公共卫生问题。根据联合国艾滋病毒/艾滋病联合规划署 (UNAIDS) 的数据,2020 年,约有 3770 万人感染艾滋病毒。其中,3600 万为成年人,170 万为 0-14 岁的儿童。此外,超过一半 (53%) 是女孩和妇女。此外,2020 年全球报告了 150 万例新的艾滋病毒病例。同样,肝炎是由病毒感染引起的肝脏感染。肝炎病毒的主要类型是 A、B、C、D 和 E。根据世界卫生组织 (WHO) 的数据,全球约有 5800 万人患有慢性丙型肝炎病毒感染,每年约有 150 万人新感染。

据世卫组织称,结核病 (TB) 是全球第 13 大死亡原因,也是继 COVID-19 之后的第二大传染病。2020 年,结核病导致 150 万人死亡(包括 214,000 名受艾滋病毒感染的人)。此外,2020 年全球有 1000 万人患有结核病,其中包括 110 万名儿童、330 万名女性和 560 万名男性。此外,医院内感染或医源性感染 (HAI) 的发病率和死亡率很高。此外,每年医疗保健系统的支出也非常巨大。美国疾病控制和预防中心 (CDC) 报告称,HAI 每年在美国医院造成约 170 万例感染病例和 99,000 例死亡。因此,全球传染病患病率的上升推动了传染病治疗市场的增长。

北美传染病治疗市场概览

北美传染病治疗市场分为美国、加拿大和墨西哥。2022 年,北美占据了全球市场的最大份额。技术进步的日益普及和研发活动的不断增加预计将加速传染病治疗市场的增长。此外,大型医疗保健企业和对治疗慢性病和病毒性疾病的先进治疗解决方案的不断增长的需求正在推动该地区的市场扩张。由于抗病毒疗法的广泛采用,对抗病毒药物的需求不断增长,预计将推动美国市场的发展。主要医药和生物制药公司专注于扩大其抗病毒药物的生产能力。例如,加利福尼亚州的吉利德科学公司于 2020 年 5 月获得了 FDA 批准其研究性抗病毒药物瑞德西韦用于治疗 COVID-19。此外,2022 年 4 月,美国食品药品监督管理局 (FDA) 批准了吉利德科学的 Veklury (瑞德西韦) 补充新药申请 (sNDA),用于治疗住院 28 天以上、体重至少 3 公斤、因 COVID-19 治疗或患有轻度至中度 COVID-19 感染的儿科患者。2021 年 9 月,拜登-哈里斯政府通过疾病控制和预防中心 (CDC) 投资 21 亿美元,以改善全国公共卫生和医疗保健部门的感染控制和预防活动。预计这些因素将在预测期内推动美国传染病治疗市场的增长。

北美传染病治疗市场收入及预测至 2030 年(百万美元)

北美传染病治疗市场细分

北美传染病治疗市场分为药物类别、适应症、给药途径、分销渠道和国家。

根据药物类别,北美传染病治疗市场细分为抗病毒、抗菌、抗真菌和其他。抗病毒部分在 2022 年占据了最大的市场份额。

就适应症而言,北美传染病治疗市场细分为 HIV、肝炎、结核病、流感、HPV 和其他。 2022 年,艾滋病毒占据了最大的市场份额。

根据给药途径,北美传染病治疗市场分为口服、肠外、外用和其他。口服部分在 2022 年占据了最大的市场份额。

在分销渠道方面,北美传染病治疗市场分为医院药房、零售药房和其他。2022 年,医院药房占据了最大的市场份额。

按国家/地区划分,北美传染病治疗市场分为美国、加拿大和墨西哥。 2022 年,美国占据了北美传染病治疗市场的主导份额。

AbbVie Inc、Astellas Pharma Inc、Bayer AG、BioCryst Pharmaceuticals Inc、F. Hoffmann-La Roche Ltd、Gilead Sciences Inc、GSK Plc、Merck & Co Inc、Pfizer Inc 和 Shionogi & Co Ltd 是北美传染病治疗市场的一些领先公司。

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Infectious Disease Therapeutics Market - Key Market Dynamics

4.1 North America Infectious Disease Therapeutics Market - Key Market Dynamics

4.2 Market Drivers

4.2.1 Rising Prevalence of Infectious Disease

4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics

4.3 Market Restraints

4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects

4.4 Market Opportunities

4.4.1 Growing Opportunities in Developing Nations

4.4.2 Escalating Threat of Antibiotic Resistance

4.5 Future Trends

4.5.1 Rising Number of Product Approvals and Launches

4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - North America Market Analysis

5.1 North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. North America Infectious Disease Therapeutics Market Analysis - by Drug Class

6.1 Overview

6.2 Anti-Viral

6.2.1 Overview

6.2.2 Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

6.3 Anti-bacterial

6.3.1 Overview

6.3.2 Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

6.4 Anti-fungal

6.4.1 Overview

6.4.2 Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

6.5 Others

6.5.1 Overview

6.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Infectious Disease Therapeutics Market Analysis - by Indication

7.1 Overview

7.2 HIV

7.2.1 Overview

7.2.2 HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.3 Hepatitis

7.3.1 Overview

7.3.2 Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Tuberculosis

7.4.1 Overview

7.4.2 Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.5 Influenza

7.5.1 Overview

7.5.2 Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.6 HPV

7.6.1 Overview

7.6.2 HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.7 Others

7.7.1 Overview

7.7.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Infectious Disease Therapeutics Market Analysis - by Route of Administration

8.1 Overview

8.2 Oral

8.2.1 Overview

8.2.2 Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8.3 Parenteral

8.3.1 Overview

8.3.2 Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8.4 Topical

8.4.1 Overview

8.4.2 Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8.5 Others

8.5.1 Overview

8.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Infectious Disease Therapeutics Market Analysis - by Distribution Channel

9.1 Overview

9.2 Hospital Pharmacies

9.2.1 Overview

9.2.2 Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9.3 Retail Pharmacies

9.3.1 Overview

9.3.2 Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9.4 Others

9.4.1 Overview

9.4.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Infectious Disease Therapeutics Market - Country Analysis

10.1 North America Infectious Disease Therapeutics Market Overview

10.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country

10.1.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country

10.1.1.2 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.2.1 Overview

10.1.1.3 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.3.1 United States: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.3.2 United States: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.3.3 United States: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.3.4 United States: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.4 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.4.1 Overview

10.1.1.5 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.5.1 Canada: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.5.2 Canada: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.5.3 Canada: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.5.4 Canada: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.6 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.6.1 Overview

10.1.1.7 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.7.1 Mexico: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.7.2 Mexico: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.7.3 Mexico: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.7.4 Mexico: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

11.1 Overview

11.2 Growth Strategies in the Infectious Disease Therapeutics Market

11.3 Inorganic Growth Strategies

11.3.1 Overview

11.4 Organic Growth Strategies

11.4.1 Overview

12. Company Profiles

12.1 Pfizer Inc

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Gilead Sciences Inc

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 F. Hoffmann-La Roche Ltd

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 Shionogi & Co Ltd

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Bayer AG

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 BioCryst Pharmaceuticals Inc

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 GSK Plc

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 AbbVie Inc

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6 Key Developments

12.9 Merck & Co Inc

12.9.1 Key Facts

12.9.2 Business Description

12.9.3 Products and Services

12.9.4 Financial Overview

12.9.5 SWOT Analysis

12.9.6 Key Developments

12.10 Astellas Pharma Inc

12.10.1 Key Facts

12.10.2 Business Description

12.10.3 Products and Services

12.10.4 Financial Overview

12.10.5 SWOT Analysis

12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners

List of Tables

Table 1. North America Infectious Disease Therapeutics Market Segmentation

Table 2. Diseases and Funding

Table 3. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class

Table 4. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication

Table 5. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration

Table 6. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 7. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country

Table 8. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 9. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 10. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 11. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 12. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 13. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 14. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 15. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 16. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class

Table 17. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication

Table 18. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 19. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 20. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market

Table 21. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

List of Figures

Figure 1. North America Infectious Disease Therapeutics Market Segmentation, by Country

Figure 2. Impact Analysis of Drivers and Restraints

Figure 3. North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

Figure 4. North America Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)

Figure 5. Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 6. Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 7. Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. North America Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)

Figure 10. HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 11. Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 15. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 16. North America Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)

Figure 17. Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 19. Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 20. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 21. North America Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)

Figure 22. Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 23. Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 24. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 25. North America Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)

Figure 26. North America Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)

Figure 27. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 28. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 29. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)

Figure 30. Growth Strategies in the Infectious Disease Therapeutics Market

1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. BioCryst Pharmaceuticals Inc
5. F. Hoffmann-La Roche Ltd
6. Gilead Sciences Inc
7. GSK Plc 
8. Merck & Co Inc
9. Pfizer Inc
10. Shionogi & Co Ltd

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America infectious disease therapeutics market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the North America infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America infectious disease therapeutics market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440